1. Table of Contents
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 Hyperbilirubinemia Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
2.2.1 Hyperbilirubinemia Clinical Trials by Region
2.2.2 Average Enrollment of Hyperbilirubinemia Clinical Trials
2.2.3 Companies participating in Trials
2.2.4 Drugs under Study for Hyperbilirubinemia Treatment, 2019

3. Region wise Hyperbilirubinemia Clinical Trials
3.1 Asia Pacific Hyperbilirubinemia Clinical Trials by Country
3.2 Europe Hyperbilirubinemia Clinical Trials by Country
3.3 North America Hyperbilirubinemia Clinical Trials by Country
3.4 Middle East and Africa Hyperbilirubinemia Clinical Trials by Country
3.5 South and Central America Hyperbilirubinemia Clinical Trials by Country

4. Hyperbilirubinemia Clinical Trial Trends
4.1 Start Year wise Hyperbilirubinemia Clinical Trials
4.2 Phase wise Hyperbilirubinemia Clinical Trials
4.3 Trial Status wise Hyperbilirubinemia Clinical Trials
4.4 Trial Type wise Hyperbilirubinemia Clinical Trials

5. Hyperbilirubinemia Average Enrollment Trends
5.1 Average Enrollment in Hyperbilirubinemia Trials by Year
5.2 Average Enrollment in Hyperbilirubinemia Trials by Phase
5.3 Average Enrollment in Hyperbilirubinemia Trials by Status
5.4 Average Enrollment in Hyperbilirubinemia Trials by Type of Trial

6. Companies Participating in Hyperbilirubinemia Clinical Trials
6.1 Hyperbilirubinemia Trials by Sponsor Type
6.2 Hyperbilirubinemia Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7 Trial Snapshots- Phase, Type, Title, Location, Start Year, Completion Year, Recruitment Status, Enrollment, Participating Countries, Trial Locations, Company, Drugs and Other Details
7.1 Hyperbilirubinemia Trials- Phase 1
7.2 Hyperbilirubinemia Trials- Phase 2
7.3 Hyperbilirubinemia Trials- Phase 3
7.4 Hyperbilirubinemia Trials- Phase 4

8. Appendix
8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List of Figures
Figure 1: Hyperbilirubinemia Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific – Country wise Hyperbilirubinemia Clinical Trials and Enrolment
Figure 5: Europe – Country wise Hyperbilirubinemia Clinical Trials and Enrolment
Figure 6: Middle East Africa – Country wise Hyperbilirubinemia Clinical Trials and Enrolment
Figure 7: North America – Country wise Hyperbilirubinemia Clinical Trials and Enrolment
Figure 8: South and Central America – Country wise Hyperbilirubinemia Clinical Trials and Enrolment
Figure 9: Hyperbilirubinemia Clinical Trials by Phase
Figure 10: Hyperbilirubinemia Clinical Trials by Trial Status
Figure 11: Hyperbilirubinemia Clinical Trials by Type
Figure 12: Hyperbilirubinemia Clinical Trials by Sponsor Type
Figure 13: Hyperbilirubinemia Clinical Trials by Leading Sponsors
Figure 14: Hyperbilirubinemia Average Enrollment by Phase
Figure 15: Hyperbilirubinemia Average Enrollment by Trial Status
Figure 16: Hyperbilirubinemia Average Enrollment by Type
Figure 17: Hyperbilirubinemia- Average Enrolment by Type of Sponsors
Figure 18: Hyperbilirubinemia- Enrolment by Leading Sponsors
Figure 19: VPAResearch- Research Methodology

List of Tables
Table 1: Hyperbilirubinemia Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific – Country wise Hyperbilirubinemia Clinical Trials and Enrolment
Table 5: Europe – Country wise Hyperbilirubinemia Clinical Trials and Enrolment
Table 6: Middle East Africa – Country wise Hyperbilirubinemia Clinical Trials and Enrolment
Table 7: North America – Country wise Hyperbilirubinemia Clinical Trials and Enrolment
Table 8: South and Central America – Country wise Hyperbilirubinemia Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Hyperbilirubinemia Average Enrollment by Phase
Table 15: Hyperbilirubinemia Average Enrollment by Trial Status
Table 16: Hyperbilirubinemia Average Enrollment by Type
Table 17: Hyperbilirubinemia- Average Enrolment by Type of Sponsors
Table 18: Hyperbilirubinemia- Enrolment by Leading Sponsors

Companies mentioned
Celgene Corp, GVK Biosciences Pvt Ltd, Hanmi Science Co Ltd, InfaCare Pharmaceutical Corp, TAKE Solutions Ltd, Wellcome Trust